– By Barry Cohen
Here’s a switch: Analysts are predicting sales for a Sanofi (NASDAQ:SNY) blockbuster drug that exceeds the company’s forecast.
Jefferies analysts wrote Dupixent revenue is likely to peak at $12.5 billion, according to an article in FiercePharma. That’s about 8% higher than Sanofi CEO Paul Hudson has set for the medication.
Dupixent is the first biologic medication approved by the Food and Drug Administration for adults and children aged six years and up with moderate to severe atopic dermatitis for whom topical treatments have not worked or are not advised.
Atopic is the most common type of eczema, affecting more than 9.6 million children and about 16.5 million adults in the United States, according to the National Eczema Association. It’s a chronic condition that can come and go for years or throughout life and can overlap with other types of eczema. The condition triggers inflammation that damages